Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder
|ClinicalTrials.gov Identifier: NCT00025935|
Recruitment Status : Recruiting
First Posted : November 1, 2001
Last Update Posted : January 23, 2018
|Condition or disease|
|Mood Disorder Bipolar Disorder|
Hide Detailed Description
Irritability is a common and impairing clinical presentation in youth (Collishaw et al 2010, Leibenluft 2011, Peterson et al 1996). Despite its significant public health impact, the clinical course and pathophysiology of irritability remains poorly understood. Chronic and severe irritability is the primary symptom of the new DSM-5 diagnosis, disruptive mood dysregulation disorder (DMDD) (APA 2013), is an associated symptom of other pediatric disorders (Ambrosini et al 2013, Burke et al 2014, Jensen et al 2007, Shaw et al 2014, Stoddard et al 2014), and can be a clinical precursor to Major Depressive Disorder (MDD) and anxiety disorders. In addition, irritability is a trait distributed continuously in youth (Stringaris & Taylor 2015), thereby fitting well within the National Institute of Mental Health (NIMH) Research Domain Criteria (RDoC) initiative (Insel et al 2010).
Clinically impairing irritability in children and adolescents began to gain more attention as interest grew in the diagnosis of pediatric bipolar disorder (Baroni et al 2009, Biederman et al 1998, Carlson 1998, Leibenluft et al 2003, Nottelman 2001). Beginning in the 1990s, child psychiatry researchers suggested that while pediatric bipolar disorder can present with distinct episodes of mania or hypomania as in adults, the more typical pediatric presentation was chronic, severe irritability and hyperarousal symptoms. However, data collected under this protocol comprise a series of longitudinal (Deveney et al 2015, Stringaris et al 2010), family (Brotman et al 2007), behavioral (Dickstein et al 2007, Rich et al 2008b), and pathophysiological (Adleman et al 2012, Adleman et al 2011, Brotman et al 2010, Rich et al 2007, Thomas et al 2014, Thomas et al 2012, Thomas et al 2013, Tseng et al 2016) studies that differentiated classically defined episodic pediatric bipolar disorder from chronic irritability without distinct manic or hypomanic episodes [see (Leibenluft 2011) for review]. These findings are consistent with reports from other groups and meta-analyses (Althoff et al 2014; Copeland et al 2014; Fristad et al 2016; Vidal-Ribas et al 2016).
Among the several strands of research designed to differentiate pediatric bipolar disorder from chronic irritability, longitudinal studies provide the strongest evidence that these two phenotypes are distinct. Children with chronic irritability are at elevated risk for later depression, but not manic episodes (Althoff et al 2014, Brotman et al 2006, Leibenluft et al 2006, Stringaris et al 2010, Stringaris et al 2009, Vidal-Ribas et al 2016). Thus, youth with MDD (with and without prior DMDD) are an important comparison group to explore, and we are examining the developmental trajectory, phenomenology, behavioral correlates, and underlying neural mechanisms of chronic irritability and MDD in youth.
The current translational model of irritability emphasizes the role of abnormal threat and reward processing, but also underlines the relevance of environmental factors in the emergence and maintenance of irritability (Brotman et al., 2017). More precisely, it is assumed that irritable children experience environments, where rewards and punishments are inconsistently delivered leading to unintentional reinforcement of disruptive behavior through the parents. Reasons for this inconsistent parent behavior could be manifold spanning instrumental learning deficits and exaggerated responses to threat and frustrative non-reward in the parents themselves as well as lack of knowledge regarding learning principles (Soenens et al., 2006; Sanders et al., 1999) and increased levels of stress (Kiff et al., 2011). These factors might contribute to instrumental-learning deficits in the children increasing frequency and intensity of temper outbursts. Heightened levels of chronic irritability, another symptom of DMDD, might be more associated with features of the parent-child interaction. There is a rich literature within the framework of attachment theory (Ainsworth et al. 2015, Bolwby, 2008) showing that behavior of children with anxious-resistant insecure attachment is characterized by a general angry tone and is also associated with increased amygdala responses to negative social scenes (Vrticka et al., 2012). In addition, it was also shown that highly irritable infants are less sociable in terms of being less responsive and more fearful towards others and displaying an angry emotional tone in general as toddlers when they had been insecurely attached and more sociable when they had been securely attached (Stupica et al, 2011). Adding another layer of complexity, it is also conceivable that inconsistent parent behavior diminishes parent s perceived trust-worthiness. This could be of relevance as recent studies showed that persons are less willing to delay rewards an action bound to increase levels of frustration if their interaction partner is perceived as little reliable (Michaelson, 2013, Front Psychol; Michaelson & Munakata, 2016 Dev Science).
The overall goal is to gain a clearer understanding of the environmental factors contributing to irritability in order to inform treatment and improve the outcome for children. In order to advance this aim, we plan to investigate parents of youth with DMDD enrolled in this study and subthreshold DMDD enrolled in this study in order to determine clinical, behavioral, neuropsychological, neurophysiological and neuroanatomical features of the parents that contribute to the symptomatology in the children and adolescents. Further, we plan to examine parent-child interaction and its influence on irritability observed in the youth.
There are 5 separate populations being studied in this protocol:
Children and adolescents between the ages of 7-17 years old who meet criteria for DMDD or subthreshold DMDD.
Parents of children and adolescents, who meet criteria for DMDD or subthreshold DMDD and are enrolled in 02-M-0021, and are 25 59 years old will be studied.
3. Healthy volunteer children and adolescents between the ages of 7-17 years old.
4. Healthy volunteer adults between the ages of 18-25 years old.
5. Children and adolescents between the ages of 12-17 years old who meet criteria for major depressive disorder (MDD).
For children and adolescents with full or subthreshold DMDD and/or MDD, this study is an outpatient characterization and longitudinal follow-along design. Once determined to be eligible, individuals come for an initial assessment, and then return at varying intervals until age 25 for clinical interviews, behavioral tasks, and structural and functional MRI.
For healthy volunteer children, adults and parents of healthy volunteer children, this study is an outpatient cross-sectional study that includes clinical interviews, behavioral tasks, and structural and functional MRI.
For all individuals, genetic material from saliva or blood is obtained under protocol 01-M-0254.
There are two primary outcome measures. First, this study will examine associations between irritability and clinical, behavioral, genetic, neuroanatomical, and neurophysiological variables in individuals with full or subthreshold DMDD and/or MDD, BD (see protocol 00-M-0198) (Leibenluft et al 2003), anxiety (see protocol 00-M-0192), and healthy volunteers (see protocol 00-M-0198). Second, this study will examine between-group differences in clinical, behavioral, genetic, neuroanatomical, and neurophysiological variables in individuals with full or subthreshold DMDD and/or MDD, BD (see protocol 00-M-0198) (Leibenluft et al 2003), anxiety (see protocol 00-M-0192), and healthy volunteers (see protocol 00-M-0198).
|Study Type :||Observational|
|Estimated Enrollment :||1850 participants|
|Official Title:||Characterization and Pathophysiology of Severe Mood and Behavioral Dysregulation in Children and Youth|
|Study Start Date :||October 29, 2001|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00025935
|Contact: Ellen Leibenluft, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Ellen Leibenluft, M.D.||National Institute of Mental Health (NIMH)|